Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for advanced bladder cancer

B J Roth1

  • 1Division of Hematology/Oncology, Indiana University Medical Center, Indianapolis, USA.

Seminars in Oncology
|October 1, 1996
PubMed
Summary

Cisplatin-based chemotherapy for advanced urothelial carcinoma offers modest benefits with significant toxicity. New agents like paclitaxel and gemcitabine are being explored to improve treatment outcomes and reduce side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Magneto-encephalogram artifacts caused by electro-encephalogram electrodes.

Medical & biological engineering & computing·2003
Same author

How epicardial electrodes influence the transmembrane potential during a strong shock.

Annals of biomedical engineering·2002
Same author

New currents in electrical stimulation of excitable tissues.

Annual review of biomedical engineering·2001
Same author

Sawtooth effect: fact or fancy?

Journal of cardiovascular electrophysiology·2001

Area of Science:

  • Oncology
  • Urothelial Carcinoma Treatment

Background:

  • Cisplatin-based chemotherapy, including methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), has been the standard for advanced urothelial carcinoma for a decade.
  • While MVAC offers modest improvements in response rates, progression-free survival, and overall survival, it is associated with moderate to severe toxicity.

Purpose of the Study:

  • To review the current landscape of chemotherapy for advanced urothelial carcinoma.
  • To identify and discuss newly recognized active agents for potential use in novel combination regimens.

Main Methods:

  • Literature review of chemotherapy regimens for advanced urothelial carcinoma.
  • Identification of emerging chemotherapeutic agents based on recent research.

Main Results:

  • Established cisplatin-based regimens provide limited survival benefits (median 12-13 months) and significant toxicity.
  • New agents such as paclitaxel, gemcitabine, ifosfamide, trimetrexate, piritrexim, and gallium nitrate have shown activity.

Conclusions:

  • Existing chemotherapy regimens for advanced urothelial carcinoma have limitations in efficacy and tolerability.
  • Novel combination regimens incorporating newly identified agents hold promise for improving patient outcomes.

Related Experiment Videos